www.alopeciaworld.com
I have received a lot of interest from others on here in my involvement with the Xeljanz trials at Yale.
I thought it would be nice for everyone if I documented my progress on here.
Xeljanz is a Jak3 inhibitor and is believed to work with alopecia by turning off the distress signal relayed by the hair follicle to the attacking immune system which is the cause of the hairs falling out. Xeljanz comes in a strength of 5mg per pill and a full box contains 60 tablets. The recommended dosage for arthritis is 1 tablet in the morning and another in the evening each day.
The trial is set in a series of stages and there are requirements before participating. These include monthly visits and blood tests every 2 weeks. Dr Brett King is absolutely fantastic and is an inspiration to me. His positivity and enthusiasm gives me the much needed hope I have craved for over a decade. I have been put on a low dose to start with which is 1 tablet every other day. My dosage has now been increased to 1 tablet every day and next month it could be increased to 2 tablets per day depending on the results.
I have completed my first month and have already noticed my alopecia has stabilised . I have not lost any existing hairs. In addition to this I have seen little hairs growing in my chest area as well as eyebrows. Fingers crossed! To date, I have experienced no side effects.
-----------------------------
AW: Other discussions on Xeljanz / Tofacitinib
https://alopeciaworld.com/main/search/search?q=Tofacitinib
Tags:
Hi Rascalx2 and FootballFan...
Dr. Ko responded to me and said he's had patients that have fuzz at 6 months, and then months 7-10 of taking 20mg, it starts to grow. There's still hope. Saw Dr. Mesinkovska yesterday and she did say that Jakafi (the expensive one) works on Xeljanz non-responders, she actually opened a study in Feb. at UCI. I've had Alopecia for so long, I go bald 95% of the time - my husband, friends and kids are fantastic about it. I was my largest hurdle. I am so sorry you are a newbie, I would not want to go back to the years of AA or the beginning years of Alopecia, I have the utmost sympathy - but I will say if I had a do-over, I would not hide it. The years of untangling and coming "out of the closet" were beyond! I can also be on Xeljanz and go through this process and not feel like I'm holding onto this hair with the same desperation as I once lived. Good luck, I would stay on it for a year - you have fuzz! Oh, another note - I am dairy free, GF - I don't think it makes much of a difference. I had hair grow in when I was at my most unhealthiest (partying in HS and college) and fall out during happy and healthy times....we need to realize the predictability is it's unpredictable!
For Football, try to switch your JAK, you might be better attacking T1&T2, rather than T3.
Good luck to all, this disease is a crazy a** rollercoaster, but it has made me a better mom and being! So cliché, but true!!!
I agree! There is something going on within that triggers the attack within the body itself. Could also be environmental which would be thought provoking!
I heard Ruxolitinib is cheaper in Turkey around $2000, but i am not sure. do you think we can buy powder in China and make it as pills. The powder is very cheap.$400/gram BTW, do you think the Barcibit will be cheaper than Ruxolitinib?
It may be another year out...but it is coming. If it is on label use, it will be a much easier drug to have covered by insurance.
__________________________________________
CTP-543, or '543 for convenience, is the company's second wholly-owned product candidate which is being developed for the treatment of moderate to severe alopecia areata, which is a common autoimmune disorder affecting millions of people in the U.S. - it causes partial or widespread loss of hair on the scalp and/or body. This candidate was revealed recently and is a deuterium-modified analog of ruxolitinib, which is commercially available as Jakafi for the treatment of myelofibrosis and polycythemia vera.
Jakafi has been used to treat alopecia areata in investigator-sponsored trials and has shown to promote hair growth in patients with this condition. Concert has conducted pre-clinical studies which demonstrated that '543 retains Jakafi's selective JAK 1/2 inhibition profile and that it shows improved metabolic stability. I think these patients will be highly motivated to try a new treatment option, especially the female part of the patient population. '543 could be the first-in-class oral medicine for alopecia areata and I think it has blockbuster potential. I believe it could be priced lower than Jakafi but that the size of the patient population is more than enough for Concert to generate $500 million to $1 billion in annual sales in 2020's.
Thank you so much for writing this, I have been so down lately and I keep praying that a treatment that WORKS becomes available to us.
That is great news!
Any mention of products and services on Alopecia World is for informational purposes only; it does not imply a recommendation or endorsement by Alopecia World. Nor should any statement or representation on this site be construed as professional, medical or expert advice, or as pre-screened or endorsed by Alopecia World. Alopecia World is not responsible or liable for any of the views, opinions or conduct, online or offline, of any user or member of Alopecia World.
© 2024 Created by Alopecia World. Powered by